熱門資訊> 正文
IceCure任命Meir Peleg为首席财务官
2026-03-24 21:01
- IceCure Medical (ICCM) announced on Tuesday the appointment of Meir Peleg as its chief financial officer, effective May 17, 2026.
- In addition, IceCure plans to appoint Richard E. Fine in the second quarter of 2026 as the company's medical director to lead breast indications. In this role, Fine will support IceCure's clinical and educational initiatives in breast cryoablation, including the company's previously announced FDA-approved ChoICE post-marketing study evaluating ProSense® cryoablation for the treatment of low-risk breast cancer.
- In alignment with IceCure's corporate strategy and technological roadmap, the company has initiated a search for a new chief technology officer. Naum Muchnik, IceCure's Vice President of R&D and Engineering, will be departing his role effective April 12, 2026. IceCure thanks Mr. Muchnik for his contributions during his tenure.
- ICCM +5.08% premarket to $0.6699.
- Source: Press Release
More on IceCure Medical
- IceCure Medical GAAP EPS of -$0.24, revenue of $3.38M
- Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag
- Seeking Alpha’s Quant Rating on IceCure Medical
- Historical earnings data for IceCure Medical
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。